Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crawford Resigns; NCI Director Von Eschenbach Named To Top FDA Spot

This article was originally published in The Pink Sheet Daily

Executive Summary

Von Eschenbach appointed to be acting FDA commissioner following the Sept. 23 resignation of Lester Crawford.

You may also be interested in...



Sweeping Changes At CDER Recommended In IoM Drug Safety Report

Among solutions suggested is six-year fixed term for the FDA commissioner and appointment of external advisory board to oversee cultural changes.

Sweeping Changes At CDER Recommended In IoM Drug Safety Report

Among solutions suggested is six-year fixed term for the FDA commissioner and appointment of external advisory board to oversee cultural changes.

No Double Duty For Von Eschenbach; Niederhuber To Run NCI

John Niederhuber, recently tapped to be NCI deputy director for translational and clinical sciences, will assume the position of chief operating officer, handling day-to-day management of the cancer institute.

Related Content

Topics

UsernamePublicRestriction

Register

PS062940

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel